Furthermore, KFF reports that the number of prescriptions increased by more than 400% between 2019 and 2023, and in 2023, spending per prescription before rebates reached more than $900
10.1208/s12248-008-9022-y AAPS J
En los ltimos aos, el mundo de la medicina ha observado un avance significativo en el tratamiento de la obesidad y el manejo del peso corporal gracias al desarrollo de los anlogos de GLP-1 (a-GLP1 en adelante)
The company (who owns Express Scripts) that sells GLP-1 coverage to employers across America and profits from administering those benefits decided it was too expensive for their own employees
These effects dont always end treatment, but they often lead to changes
Mol Cell Endocrinol 500:110628 Rhee SY, Han KD, Kwon H, Park SE, Park YG, Kim YH, Yoo SJ, Rhee EJ, Lee WY (2020) Association between glycemic status and the risk of parkinson disease: a nationwide population-based study